Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reduced pre-movement subthalamic beta desynchronization marks motor deficit in Parkinson's disease.

Brain communications·2026

Same author

Spezi Data Pipeline: Streamlining FHIR-based interoperable digital dealth data workflows.

NPJ digital medicine·2026

Same author

Common Electrophysiology Biomarkers Collected at Home Robustly Track Depression Recovery With Deep Brain Stimulation.

medRxiv : the preprint server for health sciences·2026

Same author

Profiling of fatty acids and lipids in animal and human tissues yields new leads for disease progression biomarkers of X-linked adrenoleukodystrophy.

The Journal of biological chemistry·2026

Same author

Real-Time Kinematic Adaptive Deep Brain Stimulation Safely Reduces Gait Impairment and Freezing of Gait in Parkinson's Disease.

medRxiv : the preprint server for health sciences·2026

Same author

At home monitoring of chronic adaptive deep brain stimulation for Parkinson's disease.

Brain stimulation·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Quantitative DigitoGraphy: a Comprehensive Real-Time Remote Monitoring System for Parkinson's Disease.

Shannon L Hoffman¹, Paul Schmiedmayer², Aryaman S Gala¹

¹Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.

Research Square

|February 12, 2024

Summary

QDG-Care is a new platform for Parkinson's disease (PD) that provides real-time motor symptom data and medication adherence monitoring. This technology aims to improve care access and quality for people with Parkinson's disease (PWP).

More Related Videos

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Jun 19, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Published on: July 14, 2023

Area of Science:

Neurology
Digital Health
Biomedical Engineering

Background:

People with Parkinson's disease (PWP) experience challenges with neurological care access, motor symptom assessment, and medication management.
Current methods for monitoring Parkinson's disease (PD) symptoms and medication adherence are often inadequate, leading to suboptimal patient outcomes.

Conclusions:

QDG-Care technology shows significant potential to enhance access, equity, and quality of care for people with Parkinson's disease (PWP).
The platform can improve adherence to complex medication regimens and facilitate rapid therapeutic development decisions.
High-resolution data from QDG-Care can reduce trial costs, participant numbers, and enable more diverse recruitment for new therapeutics.